Page last updated: 2024-09-03

garenoxacin and levofloxacin

garenoxacin has been researched along with levofloxacin in 36 studies

Compound Research Comparison

Studies (garenoxacin)	Trials (garenoxacin)	Recent Studies (post-2010) (garenoxacin)	Studies (levofloxacin)	Trials (levofloxacin)	Recent Studies (post-2010) (levofloxacin)
195	19	46	4,346	581	2,209

Protein Interaction Comparison

Protein	Taxonomy	garenoxacin (IC50)	levofloxacin (IC50)
Replicase polyprotein 1ab	Betacoronavirus England 1		7.6

Research

Studies (36)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	25 (69.44)	29.6817
2010's	10 (27.78)	24.3611
2020's	1 (2.78)	2.80

Authors

Authors	Studies
Bronstein, JC; Domagala, JM; Dunham, SA; Ellsworth, EL; Gage, JW; Gracheck, SJ; Hanna, DL; Huband, MD; Joannides, ET; Liu, JY; Nguyen, DQ; Sanchez, JP; Shapiro, MA; Showalter, HD; Singh, R; Stier, MA; Tran, TP; Watson, BM	1
Cohen, MA; Ellsworth, E; Gage, JW; Gibson, GW; Gracheck, SJ; Hanna, DL; Huband, MD; Skerlos, LA; Stier, MA; Sulavik, MC; Zurack, M	1
Aubry, A; Cambau, E; Jarlier, V; Matrat, S; Petrella, S; Sougakoff, W	1
Sasaki, T; Takahata, M; Yamazaki, T	1
Ho, YR; Hung, KH; Janapatla, RP; Wu, CW; Wu, HM; Wu, JJ; Yan, JJ	1
Hibi, T; Muraoka, H; Nishizawa, T; Suzuki, H	1
Fujioka, T; Hasegawa, M; Ikeda, F; Kobayashi, I; Kodama, M; Murakami, K; Muraoka, H; Okimoto, T; Saika, T; Takigawa, M; Tanahashi, J	1
Hirakata, Y; Imamura, Y; Izumikawa, K; Kakeya, H; Kamihira, S; Kohno, S; Seki, M; Sugahara, K; Yamamoto, K; Yamamoto, Y; Yanagihara, K	1
Inagaki, H; Ito, M; Kawakami, K; Matsuhashi, N; Miyauchi, R; Ohki, H; Takahashi, H; Takemura, M	1
Distèche-Nguyen, M; Gerards, T; Luxen, A; Miguet, L; Pasha, FA; Thomas, A; Zervosen, A	1
Inagaki, H; Kitamura, T; Komoriya, S; Kuroyanagi, J; Miyauchi, RN; Nagamochi, M; Odagiri, T; Sugimoto, Y; Takahashi, H	1
Inagaki, H; Kitamura, T; Komoriya, S; Nagamochi, M; Odagiri, T; Takahashi, H	1
Blaskovich, MAT; Pham, TDM; Ziora, ZM	1
Biedenbach, DJ; Jones, RN; Pfaller, MA	1
Bonner, D; Fung-Tomc, J; Gradelski, E; Kolek, B; Valera, L	1
Barrett, JF; Chaniewski, S; Frosco, M; Hooper, DC; Lawrence, LE; Ryan, B; Yang, H	1
Barrett, JF; Frosco, M; Ho, H; Lawrence, LE; Mazzucco, CE; Ryan, BM; Warr, G	1
Appelbaum, PC; Bozdogan, B; Clark, CL; Davies, TA; Dewasse, B; Jacobs, MR; Nagai, K	1
Frisbee-Hume, S; Ho, DH; LeBlanc, BM; Rolston, KV; Streeter, H	1
Ameyama, S; Shinmura, Y; Takahata, M	1
Piddock, L; Ricci, V	1
Almaraz, F; Baquero, F; Cantón, R; Jones, RN; Loza, E; Martín, R; Morosini, MI; Pascual, A; Perea, E; Tubau, F	1
Entenza, JM; Glauser, MP; Moreillon, P; Vouillamoz, J	1
Baltch, AL; Bopp, LH; Carpenter, AN; Halse, TA; Ritz, WJ; Smith, RP	1
Barcia-Macay, M; Mingeot-Leclercq, MP; Seral, C; Tulkens, PM; Van Bambeke, F	1
Michot, JM; Mingeot-Leclercq, MP; Seral, C; Tulkens, PM; Van Bambeke, F	1
Blondeau, JM; Hansen, GT	1
Gidoh, M	1
Baba, S; Fujisawa, T; Harabuchi, Y; Ikeda, F; Kobayashi, T; Kurono, Y; Nishimura, T; Suzuki, K; Ubukata, K; Yamanaka, N	1
Fukushima, K; Hayama, Y; Ikeda, T; Nakatsubo, M; Niju, T; Noda, M; Oniki, S; Saito, Y; Tsuruta, N; Uenami, T	1
Fujita, S; Hata, A; Kaji, R; Katakami, N; Kitajima, N; Masuda, Y; Ose, T; Takashima, K; Takeshita, J; Tanaka, K	1
Kurokawa, M; Nakamura, F; Nannya, Y; Shinohara, A; Taoka, K; Uni, M; Yamazaki, S; Yoshimi, A	1
Akahoshi, Y; Ashizawa, M; Ishihara, Y; Kako, S; Kanda, J; Kanda, Y; Kawamura, K; Kikuchi, M; Kimura, SI; Machishima, T; Nakano, H; Nakasone, H; Nishida, J; Sakamoto, K; Sato, M; Terasako-Saito, K; Ugai, T; Wada, H; Yamasaki, R; Yamazaki, R	1
Hasegawa, H; Izumikawa, K; Kaku, N; Kosai, K; Miyazaki, T; Morinaga, Y; Mukae, H; Murata, M; Sasaki, D; Uno, N; Yamauchi, S; Yanagihara, K	1
Funaishi, K; Hattori, N; Katsutani, S; Kawamoto, K; Matsumoto, N; Matsumoto, Y; Ohashi, N; Taniwaki, M; Yamasaki, M	1
Imuta, N; Iuchi, H; Kiyama, S; Kurono, Y; Nishi, J; Ohori, J; Yamashita, M	1

Reviews

1 review(s) available for garenoxacin and levofloxacin

Article	Year
Quinolone antibiotics. MedChemComm, 2019, Oct-01, Volume: 10, Issue:10 Topics:	2019

Trials

1 trial(s) available for garenoxacin and levofloxacin

Article	Year
Comparison of levofloxacin and garenoxacin for antibacterial prophylaxis during neutropenia. International journal of hematology, 2017, Volume: 105, Issue:6 Topics: Acute Disease; Adolescent; Adult; Aged; Allografts; Anti-Bacterial Agents; Bacteremia; Female; Fluoroquinolones; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Levofloxacin; Male; Middle Aged; Neutropenia; Retrospective Studies	2017

Article

Year

Comparison of levofloxacin and garenoxacin for antibacterial prophylaxis during neutropenia.

International journal of hematology, 2017, Volume: 105, Issue:6

Topics: Acute Disease; Adolescent; Adult; Aged; Allografts; Anti-Bacterial Agents; Bacteremia; Female; Fluoroquinolones; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Levofloxacin; Male; Middle Aged; Neutropenia; Retrospective Studies

2017

Other Studies

34 other study(ies) available for garenoxacin and levofloxacin

Article	Year
3-aminoquinazolinediones as a new class of antibacterial agents demonstrating excellent antibacterial activity against wild-type and multidrug resistant organisms. Journal of medicinal chemistry, 2006, Nov-02, Volume: 49, Issue:22 Topics: Anti-Bacterial Agents; Bacteria; DNA Topoisomerase IV; Drug Resistance, Multiple, Bacterial; Enzyme Inhibitors; Gram-Negative Bacteria; Gram-Positive Bacteria; Methicillin Resistance; Microbial Sensitivity Tests; Quinazolinones; Structure-Activity Relationship; Topoisomerase II Inhibitors	2006
In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:4 Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Drug Resistance, Multiple; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Microbial Sensitivity Tests; Pyrrolidines; Quinazolinones; Topoisomerase II Inhibitors	2007
Expression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolones. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:5 Topics: Anti-Infective Agents; DNA; DNA Gyrase; DNA, Superhelical; Enzyme Inhibitors; Mycobacterium leprae; Quinolones; Topoisomerase II Inhibitors	2007
Activity of Garenoxacin against Macrolide-Susceptible and -Resistant Mycoplasma pneumoniae. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:6 Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Macrolides; Microbial Sensitivity Tests; Mycoplasma pneumoniae	2007
Emergence of fluoroquinolone resistance in group B streptococcal isolates in Taiwan. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:5 Topics: Bacterial Proteins; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Mutation; Ofloxacin; Streptococcus agalactiae; Taiwan	2008
Sitafloxacin and garenoxacin may overcome the antibiotic resistance of Helicobacter pylori with gyrA mutation. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:4 Topics: Anti-Infective Agents; DNA Gyrase; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Helicobacter pylori; Mutation	2009
Sitafloxacin activity against Helicobacter pylori isolates, including those with gyrA mutations. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:7 Topics: Anti-Bacterial Agents; DNA Gyrase; Fluoroquinolones; Helicobacter pylori; Levofloxacin; Microbial Sensitivity Tests; Mutation; Ofloxacin	2009
In vitro activity of garenoxacin against Streptococcus pneumoniae mutants with characterized resistance mechanisms. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:8 Topics: Anti-Bacterial Agents; DNA Gyrase; DNA Topoisomerases; Drug Resistance, Bacterial; Fluoroquinolones; Microbial Sensitivity Tests; Mutation; Streptococcus pneumoniae	2009
Design, synthesis and biological evaluations of novel 7-[3-(1-aminocycloalkyl)pyrrolidin-1-yl]-6-desfluoro-8-methoxyquinolones with potent antibacterial activity against multi-drug resistant Gram-positive bacteria. Bioorganic & medicinal chemistry, 2009, Oct-01, Volume: 17, Issue:19 Topics: Anti-Bacterial Agents; Drug Design; Drug Resistance, Multiple; Gram-Positive Bacteria; Microbial Sensitivity Tests; Quinolones; Structure-Activity Relationship	2009
Discovery of new inhibitors of resistant Streptococcus pneumoniae penicillin binding protein (PBP) 2x by structure-based virtual screening. Journal of medicinal chemistry, 2009, Oct-08, Volume: 52, Issue:19 Topics: Computational Biology; Computer Simulation; Drug Discovery; Drug Evaluation, Preclinical; Drug Resistance, Bacterial; Ligands; Penicillin-Binding Proteins; Protein Binding; Streptococcus pneumoniae; Structure-Activity Relationship	2009
Design, synthesis, and biological evaluations of novel 7-[7-amino-7-methyl-5-azaspiro[2.4]heptan-5-yl]-8-methoxyquinolines with potent antibacterial activity against respiratory pathogens. Journal of medicinal chemistry, 2013, Mar-14, Volume: 56, Issue:5 Topics: Animals; Anti-Bacterial Agents; Drug Design; Fluoroquinolones; Haemophilus influenzae; Male; Mice; Microbial Sensitivity Tests; Quinolones; Rats; Respiratory Tract Infections; Spiro Compounds; Staphylococcus aureus; Streptococcus pneumoniae	2013
Design, Synthesis, and Biological Evaluation of Novel 7-[(3 aS,7 aS)-3 a-Aminohexahydropyrano[3,4- c]pyrrol-2(3 H)-yl]-8-methoxyquinolines with Potent Antibacterial Activity against Respiratory Pathogens. Journal of medicinal chemistry, 2018, 08-23, Volume: 61, Issue:16 Topics: Animals; Anti-Bacterial Agents; Drug Design; Drug Evaluation, Preclinical; Drug Resistance, Bacterial; ERG1 Potassium Channel; Escherichia coli; Female; Humans; Macaca fascicularis; Male; Methicillin-Resistant Staphylococcus aureus; Mice, Inbred CBA; Microbial Sensitivity Tests; Pneumococcal Infections; Quinolines; Respiratory Tract Infections; Streptococcus pneumoniae	2018
Activity of BMS284756 against 2,681 recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis: Report from The SENTRY Antimicrobial Surveillance Program (2000) in Europe, Canada and the United States. Diagnostic microbiology and infectious disease, 2001, Volume: 39, Issue:4 Topics: Anti-Infective Agents; Aza Compounds; Canada; Ciprofloxacin; Europe; Fluoroquinolones; Gatifloxacin; Haemophilus influenzae; Humans; Indoles; Levofloxacin; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Ofloxacin; Quinolines; Quinolones; United States	2001
Comparative killing kinetics of the novel des-fluoro(6) quinolone BMS-284756, fluoroquinolones, vancomycin and beta-lactams. International journal of antimicrobial agents, 2001, Volume: 18, Issue:1 Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacteria; beta-Lactams; Enterobacteriaceae; Enterococcus faecalis; Fluoroquinolones; Indoles; Kinetics; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Quinolones; Staphylococcus aureus; Streptococcus; Vancomycin	2001
Bactericidal activities of BMS-284756, a novel Des-F(6)-quinolone, against Staphylococcus aureus strains with topoisomerase mutations. Antimicrobial agents and chemotherapy, 2002, Volume: 46, Issue:1 Topics: Anti-Infective Agents; Aza Compounds; DNA Topoisomerases, Type I; Fluoroquinolones; Indoles; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Ofloxacin; Quinolines; Quinolones; Staphylococcus aureus	2002
Comparison of the bactericidal activities and post-antibiotic effects of the Des-F(6)-quinolone BMS-284756, levofloxacin, and ciprofloxacin against methicillin-susceptible and methicillin-resistant Staphylococcus aureus. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2002, Volume: 21, Issue:1 Topics: Anti-Infective Agents; Blood Bactericidal Activity; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Humans; Indoles; Levofloxacin; Methicillin; Methicillin Resistance; Microbial Sensitivity Tests; Ofloxacin; Quinolones; Sensitivity and Specificity; Staphylococcus aureus	2002
Single- and multistep selection study of the antipneumococcal activity of BMS-284756 compared to ciprofloxacin, levofloxacin, trovafloxacin and moxifloxacin. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2002, Volume: 8, Issue:6 Topics: Anti-Infective Agents; Aza Compounds; Biological Transport; Ciprofloxacin; Drug Resistance, Microbial; Drug Resistance, Multiple; Fluoroquinolones; Humans; Indoles; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Quinolones; Streptococcus pneumoniae	2002
Antimicrobial activity of a novel des-fluoro (6) quinolone, garenoxacin (BMS-284756), compared to other quinolones, against clinical isolates from cancer patients. Diagnostic microbiology and infectious disease, 2002, Volume: 44, Issue:2 Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Female; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Indoles; Levofloxacin; Male; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Quinolones; Sensitivity and Specificity	2002
Inhibitory activities of quinolones against DNA gyrase of Chlamydia pneumoniae. Antimicrobial agents and chemotherapy, 2003, Volume: 47, Issue:7 Topics: Anti-Infective Agents; Aza Compounds; Chlamydophila pneumoniae; DNA Gyrase; Fluoroquinolones; Gatifloxacin; Genes, Bacterial; Indoles; Levofloxacin; Molecular Sequence Data; Moxifloxacin; Ofloxacin; Quinolines; Quinolones; Topoisomerase II Inhibitors	2003
Accumulation of garenoxacin by Bacteroides fragilis compared with that of five fluoroquinolones. The Journal of antimicrobial chemotherapy, 2003, Volume: 52, Issue:4 Topics: Aza Compounds; Bacteroides fragilis; Ciprofloxacin; Fluoroquinolones; Gatifloxacin; Levofloxacin; Membrane Transport Modulators; Membrane Transport Proteins; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines	2003
[Comparative in vitro activity of garenoxacin (BMS-284756). Sentry program, Spain (1999-2000)]. Enfermedades infecciosas y microbiologia clinica, 2003, Volume: 21, Issue:8 Topics: Anti-Infective Agents; Ciprofloxacin; Enterobacteriaceae; Fluoroquinolones; Gatifloxacin; Gram-Positive Bacteria; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Pseudomonas aeruginosa; Species Specificity; Staphylococcus aureus; Streptococcus pneumoniae	2003
Efficacy of garenoxacin in treatment of experimental endocarditis due to Staphylococcus aureus or viridans group streptococci. Antimicrobial agents and chemotherapy, 2004, Volume: 48, Issue:1 Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Bacterial; Endocarditis, Bacterial; Floxacillin; Fluoroquinolones; Infusions, Intravenous; Levofloxacin; Methicillin Resistance; Microbial Sensitivity Tests; Ofloxacin; Penicillins; Rats; Staphylococcal Infections; Streptococcal Infections; Vancomycin; Viridans Streptococci	2004
In vitro activities of garenoxacin and levofloxacin against Chlamydia pneumoniae are not affected by presence of Mycoplasma DNA. Antimicrobial agents and chemotherapy, 2004, Volume: 48, Issue:6 Topics: Anti-Infective Agents; Chlamydia Infections; Chlamydophila pneumoniae; Databases, Genetic; DNA, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Mycoplasma; Ofloxacin; Reverse Transcriptase Polymerase Chain Reaction; RNA, Ribosomal, 16S	2004
Comparative activity of quinolones (ciprofloxacin, levofloxacin, moxifloxacin and garenoxacin) against extracellular and intracellular infection by Listeria monocytogenes and Staphylococcus aureus in J774 macrophages. The Journal of antimicrobial chemotherapy, 2005, Volume: 55, Issue:4 Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Cell Line, Tumor; Ciprofloxacin; Fluoroquinolones; Levofloxacin; Listeria monocytogenes; Macrophages; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Staphylococcus aureus; Time Factors	2005
Influence of efflux transporters on the accumulation and efflux of four quinolones (ciprofloxacin, levofloxacin, garenoxacin, and moxifloxacin) in J774 macrophages. Antimicrobial agents and chemotherapy, 2005, Volume: 49, Issue:6 Topics: Anti-Infective Agents; Aza Compounds; Cell Line; Ciprofloxacin; Fluoroquinolones; Heat-Shock Response; Humans; Kinetics; Levofloxacin; Macrophages; Moxifloxacin; Ofloxacin; Quinolines; Quinolones	2005
Comparison of the minimum inhibitory, mutant prevention and minimum bactericidal concentrations of ciprofloxacin, levofloxacin and garenoxacin against enteric Gram-negative urinary tract infection pathogens. Journal of chemotherapy (Florence, Italy), 2005, Volume: 17, Issue:5 Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Gram-Negative Bacterial Infections; Humans; Levofloxacin; Microbial Sensitivity Tests; Mutation; Ofloxacin; Urinary Tract Infections	2005
[In-vitro and in-vivo activities of moxifloxacin and garenoxacin against Mycobacterium leprae]. Nihon Hansenbyo Gakkai zasshi = Japanese journal of leprosy : official organ of the Japanese Leprosy Association, 2007, Volume: 76, Issue:1 Topics: Animals; Anti-Infective Agents; Aza Compounds; Drug Resistance, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Leprostatic Agents; Levofloxacin; Mice; Mice, Inbred BALB C; Mice, Nude; Moxifloxacin; Mycobacterium leprae; Ofloxacin; Quinolines; Rifampin	2007
[Mutant prevention concentrations of garenoxacin against Streptococcus pneumoniae isolates from otorhinolaryngological infections]. The Japanese journal of antibiotics, 2010, Volume: 63, Issue:4 Topics: Anti-Bacterial Agents; Aza Compounds; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Moxifloxacin; Mutation; Ofloxacin; Otorhinolaryngologic Diseases; Pneumococcal Infections; Quinolines; Streptococcus pneumoniae	2010
Anaphylaxis due to intravenous levofloxacin with tolerance to garenoxacin. Internal medicine (Tokyo, Japan), 2012, Volume: 51, Issue:13 Topics: Adult; Anaphylaxis; Anti-Bacterial Agents; Cross Reactions; Drug Hypersensitivity; Fluoroquinolones; Humans; Injections, Intravenous; Levofloxacin; Male; Ofloxacin; Pneumonia, Mycoplasma; Skin Tests	2012
[Comparison of garenoxacin and levofloxacin for the prophylaxis of febrile neutropenia]. Gan to kagaku ryoho. Cancer & chemotherapy, 2014, Volume: 41, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Febrile Neutropenia; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Middle Aged; Neoplasms; Retrospective Studies	2014
Comparison of garenoxacin with levofloxacin as antimicrobial prophylaxis in acute myeloid leukemia. Japanese journal of clinical oncology, 2015, Volume: 45, Issue:8 Topics: Adult; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Bacterial Infections; Febrile Neutropenia; Female; Fluoroquinolones; Humans; Leukemia, Myeloid, Acute; Levofloxacin; Male; Middle Aged; Primary Prevention; Retrospective Studies; Sample Size	2015
Antimicrobial agents and chemotherapy, 2018, Volume: 62, Issue:4 Topics: Drug Resistance, Bacterial; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Mutation; Quinolones; Streptococcus pneumoniae	2018
Acquired factor V inhibitor after antibiotic treatment in a patient with pneumonia: a case report. Annals of hematology, 2019, Volume: 98, Issue:8 Topics: Aged; Anti-Bacterial Agents; Antibody Specificity; Antifungal Agents; Autoantibodies; Autoimmune Diseases; Ceftriaxone; Cephalosporins; Ciprofloxacin; Drug Substitution; Drug Therapy, Combination; Factor V; Factor V Deficiency; Fluoroquinolones; Humans; Levofloxacin; Male; Meropenem; Micafungin; Partial Thromboplastin Time; Pneumonia; Prothrombin Time	2019
Effectiveness of antibacterial agents against cell-invading bacteria such as Streptococcus pyogenes and Haemophilus influenzae. BMC microbiology, 2021, 05-14, Volume: 21, Issue:1 Topics: Amoxicillin; Anti-Bacterial Agents; Cephalosporins; Clarithromycin; Fluoroquinolones; Haemophilus Infections; Haemophilus influenzae; Humans; Levofloxacin; Microbial Sensitivity Tests; Streptococcal Infections; Streptococcus pyogenes	2021